1. 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult 
Todd J. Anderson, MD, Jean Grégoire, MD, Glen J. Pearson, PharmD, Arden R. Barry, PharmD, Patrick Couture, MD, Martin Dawes, MD, Gordon A. Francis, MD, Jacques Genest, MD, Steven Grover, MD, Milan Gupta, MD, Robert A. Hegele, MD, David C. Lau, MD, PhD, Lawrence A. Leiter, MD, Eva Lonn, MD, G.B. John Mancini, MD, Ruth McPherson, MD, PhD, Daniel Ngui, MD, Paul Poirier, MD, PhD, John L. Sievenpiper, MD, PhD, James A. Stone, MD, PhD, George Thanassoulis, MD, Richard Ward, MD 
Canadian Journal of Cardiology 
Volume 32, Issue 11, Pages (November 2016)
DOI: /j.cjca
Copyright © 2016 Canadian Cardiovascular Society Terms and Conditions

2. Figure 1
Whom to screen for dyslipidemia in adults at risk. ∗Men younger than 55 years and women younger than 65 years of age in first-degree relative. BMI, body mass index.
Canadian Journal of Cardiology  , DOI: ( /j.cjca )
Copyright © 2016 Canadian Cardiovascular Society Terms and Conditions

3. Figure 2
How to screen for dyslipidemia in adults at risk. ApoB, apolipoprotein B; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides.
Canadian Journal of Cardiology  , DOI: ( /j.cjca )
Copyright © 2016 Canadian Cardiovascular Society Terms and Conditions

4. Figure 3
Non-HDL-cholesterol measures cholesterol in all atherogenic lipoproteins. ApoB, apolipoprotein B; HDL, high-density lipoprotein; IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein; LP(a), lipoprotein(a); VLDL, very low-density lipoprotein.
Canadian Journal of Cardiology  , DOI: ( /j.cjca )
Copyright © 2016 Canadian Cardiovascular Society Terms and Conditions

5. Figure 4
Conditions for which pharmacotherapy with statins is indicated. ABI, ankle-brachial index; ACR, albumin:creatinine ratio; eGFR, estimated glomerular filtration rate; LDL-C, low-density lipoprotein cholesterol; TIA, transient ischemic attack.
Canadian Journal of Cardiology  , DOI: ( /j.cjca )
Copyright © 2016 Canadian Cardiovascular Society Terms and Conditions

6. Figure 5
Nonstatin treatment algorithms. † ‡ Statins are first-line therapy but add-on or alternative therapy might be required as per the algorithm; ¶ Consider more aggressive targets for recent ACS patients; ∗∗PCSK9 inhibitors have not been adequately studied as add-on to statins for patients with diabetes and other comorbidities. ACS, acute coronary syndrome; ApoB, apolipoprotein B; BAS, bile acid sequestrants; CLEM, Cardiovascular Life Expectancy Model; CVD, cardiovascular disease; DM, diabetes mellitus; FRS, Framingham Risk Score; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PCSK9, proprotein convertase subtilisin kexin 9; Rx, prescription.
Canadian Journal of Cardiology  , DOI: ( /j.cjca )
Copyright © 2016 Canadian Cardiovascular Society Terms and Conditions